SCN2B

Across TCGA pan-cancer cohorts, SCN2B RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated SCN2B data layer compared with 3 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SCN2B RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SCN2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and LGG show a favorable association.

LIHC, LUAD, and BLCA are the cancer types where SCN2B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.423	0.573	<.001	69	view →
LUAD	OS	Tertile	All	0.738	0.596	<.001	69	view →
BLCA	OS	Median	All	0.362	0.547	.017	41	view →
ACC	DFS	Tertile	III,IV	0.326	0.722	.006	36	view →
LGG	DFS	Median	All	0.560	0.304	<.001	33	view →
UCEC	DFS	Tertile	IV	0.685	0.249	.008	32	view →
LUSC	DFS	Quartile	II,III,IV	0.297	0.562	.007	30	view →
ESCA	DFS	Median	III,IV	0.456	0.238	.010	27	view →
CHOL	DFS	Tertile	All	0.830	0.116	.010	17	view →
PRAD	DFS	Quartile	All	0.873	0.731	.002	16	view →
THCA	DFS	Tertile	All	0.930	0.654	.008	14	view →
SCLC	DFS	Median	IV	0.137	0.559	.008	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

SCN2B–LIHC (OS)

Open the LIHC breakdown →